Breast Cancer
Conference Coverage
Genotype-driven dosing reduces 5-FU, capecitabine toxicity
MUNICH – Clinic-based screening for four common variants and dose-adapted therapy reduced severe fluoropyrimidine-associated toxicity.
News
Talazoparib approved for HER2-negative advanced breast cancer
The
Feature
Tech-based cancer company raises access concerns
Oncologists say a new company that aims to link patients with cancer care and clinical trials through technology has both positives and negatives...
Conference Coverage
ESMO 2018 to highlight research on advanced breast cancer
...
Conference Coverage
MBC care causes more money problems for uninsured – but more financial stress for the insured
The uninsured more often reported material burdens; the insured reported more worry, distress, and frustration.
From the Journals
Investigators identify 21 genomic “hotspots” in breast cancers
A previously identified chromosomal translocation may be the critical initiating event in some breast cancer subtypes.
Conference Coverage
Breast cancer risk in type 2 diabetes related to adiposity
Women with type 2 diabetes mellitus have a moderately increased risk of breast cancer that appears to be mainly caused by adiposity, not diabetes...
Conference Coverage
Breast cancer patients getting unnecessary scans against recommendations
PHOENIX – Despite ASCO recommendations, many patients with early-stage breast cancers at low metastasis risk have undergone imaging tests for...
From the Journals
Metastatic breast cancer lesions immunologically depleted compared with primary
In an analysis of the immune microenvironment of breast cancer tissue samples, metastatic breast cancer lesions were relatively inert compared...
From the Journals
Outcomes similar for concurrent versus sequential treatment in HER2-positive breast cancers
Long-term results of a phase 3 trial indicate that concurrent FEC, paclitaxel and trastuzumab is not warranted, investigators say.
Latest News
Top cancer researcher fails to disclose corporate financial ties in major research journals
A senior official at Memorial Sloan Kettering Cancer Center has received millions of dollars in payments from companies that are involved in...